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Summary: 
Background: Combination antiretroviral therapy (CART) for HIV infection has resulted 
in outstanding decreases in HIV-related morbidity and mortality. However, these 
achievements need to be translated into practice. HIV care is an important element of 
the response to HIV and encompasses a continuum from early diagnosis to treatment 
outcomes. Systematic monitoring of successful entry into HIV care, retention in care and 
monitoring treatment outcomes are important elements of a response to HIV/AIDS. 
 
Objective:   We evaluated several key indicators of the quality of care in adults living 
with HIV in Croatia. 
Methods: In a retrospective analysis of reported data for 728 patients with HIV receiving 
medical care from 2007 to 2011, we determined performances for 6 HIV care healthcare 
indicators nationwide. These Indicators were: 1) patient access to HIV testing, 2) 
integration into care, 3) antiretroviral treatment guidelines compliance, 4) viral load 
suppression in patients starting CART, 5) retention into care and 6) success of care 
(survival after inclusion into care, viral suppression and CD4 cell count). A person was 
considered included into care if at least one CD4 cell count measurement was done in a 
calendar year. For the CD4 cell and viral load indicators the last measurement in a 
calendar year was used in the analysis. 
Result: Of 316 entering care at UHID in the period 2007-2011, 186 (59%) were 
diagnosed late (CD4 cell count < 350 cells/mm³). Overall, 87% of were integrated into 
care within one month of diagnosis, the percentage ranged from 79 to 94% in individual 
calendar years. Among patients who ever had a CD4 cell count between 200 and 350 
per mm³ and/or clinical AIDS the proportion of patients receiving CART was 82%, 89%, 
89%, 91% and 94% for years 2007-2011 respectively. Of 228 patients who started 
CART in the period 2007-2010; 206 (90%) had a viral load measurement after 1-year (+- 
90 days) of therapy. An undetectable viral load was found in 88% (viral load < 50 
copies/ml of HIV-1 RNA) and 97% (viral load < 400 copies/ml) of these patients. 
Retention in care was good as measured by the proportion of patients not seen in care 
in the next calendar year. The total number of patients in care ranged from 412 in 2007 
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to 637 in 2011, and lost to follow-up was 7.3% in 2007 and 6.2% in 2011. Survival after 
inclusion into care was 95%, 93% and 93% at one, two or three years respectively. The 
median CD4 cell count of all patients in care increased from 426 cells/mm³ in 2007 to 
524 cells/mm³ in 2011. The proportion of patients in care with a viral load < 400 
copies/ml increased over time. 
Conclusion:  The quality of HIV care in Croatia is very good. Late presenters remain a 
problem and efforts to promote earlier HIV diagnosis should be undertaken. Our data 
was generated on a national level, in the future, it can be used to monitor HIV public 
health policy and prevention. 
Keywords: Health care interventions, HIV, AIDS, Croatia, HIV quality of care. 
----------------------------------------------------------- 
1. Introduction: 
Without antiretroviral therapy (ART) most persons with human immunodeficiency virus 
(HIV) develop acquired immunodeficiency syndrome (AIDS) within 10-12 year after 
infection. AIDS results in important morbidity and premature death [1]. 
Antiretroviral treatment changed HIV from a fatal condition to a progressive chronic 
disease. As a chronic disease, HIV care became more complex; the need for 
standardization and guidelines became stronger. Standards of care for HIV are 
established by nationals and internationals guidelines [2-4]. In a resource limited setting, 
application of these guidelines can be challenging. This may have an impact quality of 
HIV care. State of the art care of HIV patients requires the use of multiple health care 
interventions such as disease monitoring, clinical interventions, and availability of 
antiretroviral drugs. Unfitting delivered care may have important implication for the 
health of HIV patients as well as for public health. 
Croatia is an upper-middle/high income country with a population of 4.4 million. It has a 
centralized system of treatment and care for persons infected with HIV. All patients are 
treated in Zagreb at the University Hospital for Infectious Diseases (UHID). Regarding 
HIV treatment, Croatia can be considered a country with an individual approach to 
combination antiretroviral therapy (CART). Choice of drugs is limited; there are no 
single-tablet drugs available currently 14 drugs are used. Antiretroviral drugs are only 
given from the hospital pharmacy at UHID. Heath care is free of charge for patients; 
costs of antiretroviral and monitoring are fully covered since 1998. 
Individual can be tested in 10 voluntary counseling and testing sites, tests are 
anonymous and free. All blood products are also tested since 1987. 
Surveillance activities for HIV/AIDS epidemic are performed since 1985. Since 1997, 
there is a comprehensive electronic database on HIV infected patients available at 
UHID. 
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From 2007-2011, there was approximately an average of 64 new HIV diagnosis 
annually. In 2011, 76 persons were diagnosed with HIV in Croatia, 22 were diagnosed 
with AIDS. HIV incidence is 10-14 per million inhabitants, these values place Croatia in 
the category of countries considered to have a low HIV/AIDS level epidemic. Testing 
data suggest a low prevalence even in high risk group (< 5%) [5-7]. 
Croatia’s HIV/AIDS epidemic started in 1985 when the first AIDS case was documented. 
The first cases were identified among labor migrants who returned from western Euro-
pean countries, a seafarers who acquired HIV in Africa and Eastern Asia [8]. Recent 
data suggest an emerging HIV epidemic among men who have sex with men (MSM) [5]. 
 
Quality of care measures and standard are now defined for many health care conditions. 
Efforts to measure and standardize the quality of care provided to persons infected with 
HIV had begun during 1990’s. Several papers have been written to provide HIV care 
quality measures [9-10]. The World Health Organization (WHO) has developed a set of 
indicators to monitor the health systems response to HIV/AIDS without the capability to 
monitor laboratory management of patient such as their CD4 cell count and viral loads 
[11]. The advent of antiretroviral therapy resulted in a large decrease in hospitalization 
and length of hospital stays. Therefore our assessment of HIV care is more focused on 
outpatient settings.  
 
Care of persons with HIV/AIDS is complex and require monitoring of quality indicators 
within different systems of clinical care provided to these patients. During the last few 
years, several institutions and countries have built their own cascade of care. Cascade 
of care is a visual representation of this continuum of care. It is a tool for clinicians as it 
enables them to quantify how their patients benefit from the care they received and also 
to help clinicians to identify deficiencies in continuum of care in order to improve HIV 
care [12]. It can also be used to monitor progress of HIV care in Croatia over time and 
possibly with other countries if similar methodology is used. To build our cascade of care 
we assessed 6 indicators. Our cascade begins with persons diagnosed with HIV, linked 
to care, retained in care, receiving CART, having undetectable viral load, and ends with 
success of care.  
Suppression of the viral load through treatment cascade provide clinical benefit to 
patients as it can decrease morbidity and mortality, and on a public health perspective it 
may lead to a decrease HIV transmission. Some studies showed that having a low viral 
load in the community would result in a decrease in new HIV infection and that having a 
large portion of the HIV population with CART could have an impact on reducing HIV 
transmission [13-14]. 
2. Objectives: 
Up to this date, no paper has been written, to evaluate HIV quality of care and treatment 
in Croatia. In this paper we decided to focus on care and outcome of HIV/AIDS 
treatment in Croatia. We propose strategies to define and assess HIV quality of care.  
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We analyzed 6 different indicators of care in adult patients (defined as 18 years old or 
older) living with HIV in Croatia for the 2007-2011 period. 
 
3. Methods: 
3.1 Study population: 
Patient eligible for this analysis were seen in care at UHID from 2007 to 2011. Included 
in the analysis were Croatian citizens of 18 years of age or older. All patient data was 
obtained from an electronic database in use at UHID since 1997. A person was 
considered included into care if at least one CD4 cell count measurement was done in a 
calendar year. For this study, the following data was collected: Age, sex, risk group, date 
of HIV test, date of inclusion into care, CD4 cell counts, HIV-RNA measured, whether 
the patient is receiving CART, and date of CD4 counts and HIV-RNA measured since 
last follow-up results were used as proxy measure for medical visits. 
3.2 Indicators 
Health care measures delivered to HIV patient in Croatia were assessed for 6 quality of 
care indicators.  Selected indicators regard timing of diagnosis (late diagnosis), 
integration into care, retention into care, virological and immunological indicator of 
treatment and success of care among HIV diagnosed patient. All indicators were defined 
with eligibility criteria for the measure. 
3.3 Ethics statement:  
The study is part of the project of the Ministry of Science and education for which Ethical 
Approval has been granted both by the University Hospital for Infectious Diseases 
(UHID), Zagreb, Croatia and University of Zagreb Medical School.  
4. Definitions: 
4.1 Early access to HIV testing for patients 
To access early access to HIV testing, we used the proportion of late HIV diagnosis 
among newly diagnosed persons entering care at UHID. To further evaluate the state of 
immunosuppression of our HIV patient at diagnosis, we used two definitions to define 
late presentation. We discriminated late presentation from very late presentation. Late 
diagnosis was defined by a patient presenting with a CD4+ T-cells count <350 
cells/mm³. Very late presentation was defined with a CD4 cell count <200 cells/mm³ or 
clinical AIDS. 
In this analysis we also looked at the proportion of patients who had likely acute HIV 
infection or no seroconversion within 2 years.  A clinical diagnosis of AIDS was made 
according to the European case definition [15]. 
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We also excluded from this indicator patients who were already diagnosed or treated for 
HIV prior to receiving care in our hospital.  
 
4.2 Rapid integration into care. 
 
Integration into care is the active process of engaging newly diagnosed HIV infected 
patients into HIV primary care. To assess rapid integration into care, we measured the 
length of time between the HIV diagnosis and the first CD4 count, using data from our 
HIV diagnosis and CD4 laboratory count. Rapid integration into care was considered if 
the patient received his first CD4 count within one month following HIV diagnosis.  
4.3 Compliance with current guidelines on when to start CART.  
Guidelines recommend that all patient with a CD4 cell count <350 cells/mm³, or with a 
clinical diagnosis of AIDS to receive CART [2-3]. 
To assess guidelines compliance, we monitored the proportion of patient receiving 
CART who ever had a CD4 count ≤350 cells/mm³ or had been diagnosed with an AIDS 
defining illness. This analysis was done using the CD4 measurement closest to the end 
of the calendar year. CART was defined by at least two nucleo(s)tide reverse 
transcriptase inhibitors (NRTI) plus either one non-nucleoside reverse transcriptase 
inhibitor (NNRTI), protease inhibitor (PI) or raltegravir. Excluded from the analysis were 
patients with less than 3 month in care and a CD4 cell count 200-350 cells/ mm³ as were 
patient with less than 1 month in care and a CD4 cell count less than 200 cells/mm³. 
4.4 Achieving viral load suppression, 
We defined successful viral load suppression by the proportion of patient on CART with 
a viral load <50 copies/mL after receiving CART for a year. Viral load value was taken 
from the available measurement closest to the 12th month of therapy (+- 3 months).We 
examined the HIV-1 RNA level collected from 2007 to 2011. Treatment failure was 
defined by a viral load >400 copies/mL. For the analysis, viral load levels were stratified 
as <50 or <400 copies/mL.  
4.5 Retention into care 
Integration into care and retention into care are distinct criteria on the engagement of 
care cascade. To assess the scope of HIV diagnosed patient attending UHID who are 
lost to follow up. We examined retention into care from 2007-2011. Retention was 
defined as being in care during one calendar year continuing care the following calendar 
year. We measured the proportion of patient not seen in care in the next calendar year 
using available CD4 count as proxy of engagement into care. 
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4.6 Successful care:  
-Survival of HIV patient after inclusion into care: 
Survival was estimated by the Kaplan-Meir plot. We evaluated survival for all patient 
included in HIV care at 1 year, 2 year, and 3 year after being diagnosed with HIV.  
-Efficacy of viral suppression was estimated with the proportion of patients that have an 
undetectable viral load within one calendar year.  
-Similarly, success of CD4 cell count increase was estimated with the proportion of 
patients that have a CD4 cell count >500 within one calendar year. The last CD4 count 
in a calendar year was used for this analysis. The sample population was clustered in 3 
groups: CD4<200, CD4>200-349<, CD4>350.All patients included for HIV care were 
evaluated 
All analyses were performed using the statistical software package SAS version 9.3.1 
(SAS institute Inc, Cary, North Carolina, USA); the level of significance was set at 0.05. 
 
 
5. Results: 
 
Baseline characteristic 
A total of 728 persons of 18 years of age or older were seen in UHID for HIV/AIDS care 
from 2007-2011, the majority of them were males (82-86%) and the median age for 
Adults (> 18 years of age) at last CD4 cell count measurement was 42.4 years (Table1).
 
Characterstics
2007 2008 2009 2010 2011
Patients in care 412 475 524 579 637
Age, median, years 42.2 42.2 42.4 42.1 42.4
Sex, male % 82 85 85 86 86
MSM transmission risk % 47.1 50.5 53.4 57.5 59.0
Living in Zagreb, % 34.0 32.8 35.4 35.2 35.6
CD4 cell count, 
median, cells/mm3
426 429 450 476 524
Receiving ART, % 78 80 80 82 85
Retention in care, % 93 94 93 94 94
Calendar year
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Table 1. Main characteristic of patients in care at UHID, 2007-2011. 
5.1. Early access to HIV testing for patients 
Of the 314 persons newly diagnosed with HIV between 2007-2011, 187 (60%) were 
diagnosed late (CD4 cell count < 350 cells/mm³ or clinical AIDS); very late diagnosis 
(CD4 cell count < 200 cells/mm³ or clinical AIDS) was found in 132 (42%). In 2011, 66 
patients entered care 70%% of patient were diagnosed late and 45% were diagnosed 
very late. (Figure 1.) 
 
 
Figure 1. The problem of late presentation to care, Croatia, 2007-2011. 
Of the 187 persons defined as having a late HIV diagnosis, 24 (12.8%) had acute HIV 
infection or reported a negative HIV diagnosis within the past 2 year prior to their HIV 
diagnosis. 
5.2. Rapid integration into care  
Between 2007 and 2011, 314 adults entered care with HIV infection. Among them 87% 
of persons diagnosed with HIV had a CD4 cell count within one month of HIV diagnosis. 
The percentage were 79%, 88%, 88%, 94%, 85% in year 2007-2011 respectively 
(Figure 2.) 
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Figure 2. Time of first CD4 count within one months of HIV-diagnosis in Croatia 2007-
2011. 
Of 40 patients who did not link within one month, 32 (80%) had a CD4 cell count within a 
year after HIV diagnosis. 
5.3. Compliance with current guidelines on when to start CART 
Among patients who ever had a CD4 cell count between 200 and 350 cells/mm³ the 
proportion of patients receiving CART was 88%, 92%, 91%, 93% and 96% for years 
2007-2011 respectively (Figure 3.). Compliance to guidelines increased progressively 
through the study period. In 2011, of the 479 patients with CD4 cell count <350 
cells/mm³ or clinical AIDS, 20 were not receiving CART. 
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Figure 3. Compliance with treatment guidelines. The proportion of patients with a history 
of clinical AIDS or CD4 cell count <200 cells/mm³ or a CD4 cell count between 200 and 
350/mm3 treated with CART in Croatia in the period 2007 to 2011. Included into the 
analysis were patients > 1 months in care (clinical AIDS or < 200 cells/mm3) or > 3 
months in care (CD4 cell between 200 and 350 per mm3) in a calendar year. 
 
5.4. Achieving viral load suppression after one year of CART  
Among the 291 antiretroviral naïve patients who started CART in the period 2007-2011, 
266 had a viral load measurement after one year of CART (+/- 90days). The following 
reasons for not having a measurement were observed (n=25): death (n=9), no test 
performed or unknown result (n=7), lost to follow-up (n=5), discontinuation (n=3), and 
treatment only during pregnancy (N=1).  
 Of 266 patients 257 (97%) had an undetectable viral load of < 400 copies/ml and 236 
(89%) had <50 HIV-1 RNA copies/mL. (Figure 4.) 
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Figure 4. Viral load suppression after one year on CART, Croatia, 2007-2011 
 
5.5. Retention into care:  
The total number of patient engaged in care ranged from 410 in 2007 to 637 in 2011. 
Loss of follow up, defined as not in care during one calendar year while being in care in 
the previous calendar year, was 7.3% in 2007 and 6.4% in 2011. On average 93% of 
patient attending HIV care in one year attended care the following year. Cumulatively, 
over 5 years of observation, of 369 seen in 2006 by 2011 294 (79.7%) of patient were 
continuously in HIV care. 
5.6. Successful care 
Survival after inclusion into care was 95%, 93%, 93% at one, two, or three years 
respectively (Figure 5.) 
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Figure 5. Survival after inclusion into care in the period 2007-2011. 
 
The proportion of patient with a high viral load >10000 HIV-1 RNA copies/ml decrease 
over time (figure 6.) 
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Figure 6. Viral load suppression in patients in care, Croatia, 2007-2011 
 
The median CD4 cell count of all patient in care showed an increased trend from 426 
cells/mm³ in 2007 to 524 cells/mm³ in 2011. This trend is consistent with the increase in 
suppressed viral load. 
In 2011, among 637 adults in care (regardless of CART), 78% had a CD4 >350 per 
mm3 (Figure 7.).  
 
 
Figure 7. Different CD4 cell count strata for patient in care, Croatia, 2007-2011. 
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6. Discussion 
6.1. Early access to HIV testing for patients 
Over the natural course of an HIV infection CD4 count gradually decay. Median CD4 
counts provide an indication of patient level of immunosuppression at diagnosis [16]. 
Testing and diagnose infected persons with HIV is the entry point to HIV care. Since 
2007, UHID observed an increase in the proportion of patients presenting with advanced 
HIV infections, the proportion of very late presenter was stable. The high proportion of 
late presenter was considered to be the weakest point in our cascade of care.  
Late HIV diagnosis is not only a tool to assess the efficiency of diagnostic procedure. It 
is also a major concern, such advanced disease present a poorer prognosis and it is 
associated with rapid progression to AIDS and an increase short term mortality 
compared to those diagnosed at an early stage of HIV [17]. A low CD4 count is also 
associated with an increased risk of non-AIDS related illnesses (cardiovascular, renal, 
hepatic, malignancies) [18-19]. 
Treating late presenter is also more challenging as they are more often associated with 
a higher rate of viral load failure [20]. Late presenters enter care at a stage of HIV where 
CART should have already begun. Efforts to decrease the proportion of late presenter 
could be translated into improved short term and long term mortality. 
On a public health level, advance disease presents an increased transmission risk of 
HIV, increased health care cost [21]. Persons integrated into care are less likely to en-
gage in risk transmission behaviour [22]. Posing an important barrier to reduction in inci-
dence of HIV infection. Furthermore, the proportion of late presenter could also be con-
sidered as a reflection of persons unaware of their infection.  
 
We can suppose that poor access to care might be due to cultural rather than financial 
reasons. As care is free of charge. Cultural reasons related to factor such as stigma, 
environment, and minority. More study are needed on our late presenter population to 
cluster and later on target this population. 
The level of stigma toward MSM and patient with HIV/AIDS is still high in Croatia. [23-
24]. 
The analysis of late presenters as limitations. For example, in early HIV infection a tran-
sient low CD4 (<350/mm3) can be observed. In practice these patients are difficult to 
discriminate from late presenter in routine surveillance system. As a result, this overes-
timates the number of late presenters. 
 
 
Several methods are available to expend our testing criteria to significantly decrease the 
rate of late presentation of HIV in Croatia: routine testing, targeted testing (STD), testing 
all patient aged 13-64 year’s old, community based testing, oral testing at home. 
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In 2006, in order to respond to the high rate of undiagnosed HIV infections, the CDC 
published new HIV testing guidelines calling for routine testing in all heath care settings 
[25]. By decreasing the proportion of late presenters, and thereby the proportion of 
patient unaware of their HIV status, our system will become increasingly representative 
of the HIV population in Croatia. 
 
6.2. Rapid integration into care  
From natural history of HIV infection, we know that a subclinical latent phase precede 
the appearance of opportunistic infection. Monitoring the immune systems allows us to 
considerably decrease mortality by guiding clinician to start prophylactic drug against 
opportunistic infections and; it also indicates if antiretroviral treatments should be 
started. 
It is recommended that all patients have their first CD4 count measured within two 
weeks of HIV diagnosis [26]. It is encouraging that almost nine out of ten patient with 
HIV had a CD4 count within one month of diagnosis. This demonstrates that CD4 count 
is usually requested at the time of diagnosis. 
 
6.3. Compliance with current guidelines on when to start CART 
AART in Croatia is available through the national health insurance system since 1998. In 
2007 guidelines were modified to recommend the initiation of CART at a CD4-cell count 
≤350 cell/mm³ [2-3]. Consequently, the proportion of patients starting CART at CD4-cell 
count <350 cells/mm³ increased after 2007. During this study, most patients with a CD4 
cell count <350 cells/mm³ or clinical AIDS were receiving CART therefore compliance 
with current guidelines was not a barrier to HIV care in Croatia. 
6.4. Achieving viral load suppression 
Determination of HIV-1 RNA by PCR is available in Croatia since 1997. Between 2007 
and 2011, our results show that most patients receiving CART achieved undetectable 
plasma HIV-RNA level.  
The main goal of CART is to restore the immune system through the maximal 
suppression of viral replication. A consistently suppressed HIV viral load is associated 
with a decreased risk of developing AIDS, an improved survival, and a lower probability 
of transmitting HIV, particularly by sexual contact [27]. 
In developed countries, determination of plasma viral load is considered an essential 
part for monitoring effectiveness of CART and an excellent predictor of survival. The 
virological goal of CART is to reach less than 50 copies of HIV-1 RNA per milliliter of 
plasma measured by polymerase chain reaction (PCR) by week 24. According to BHIVA 
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guidelines, standard of care is defined as 85% of patient with a viral load <50 copies/mL 
after one year on CART[28]. 
Our results were considered to be satisfying as primary drug failure is common. One 
study showed that 24% of our patients failed to show a viral load reduction after 15 
month on CART. Common factors associated with CART failure were: AIDS event, 
death, patient’s poor compliance or absorption. Viral resistance is also often associated 
with CART failure but was not evaluated in this study.  
Another indicator that we did not assess indicators is the frequency of VL testing. There 
is currently no consensus on the frequency of virological monitoring. Also, in a recent 
study, we did not observe that less frequent VL testing was associated with an increase 
in CART failure [29]. Therefore this indicator was considered less essential than 
achieving viral load suppression. 
6.5. Retention into care 
Retention in care is required for HIV patient’s optimal outcomes. For patient who are not 
on CART, retention in care allows prompt initiation of CART once indicated, delivery of 
prophylactic medication for opportunistic infections and also prevention of mother to 
child transmission. For patients receiving CART, retention in care is essential to ensure 
provision of CART, identify potential side effects, and control effect of CART. 
For all patients, retention in care provide further assistance through ancillary services 
such as social support and psychological support [30]. 
 
Current data suggests that there is no clear gold standard to evaluate retention in care 
[31]. For example, patient on CART are expected to come more frequently than patient 
who are not. Visit frequency is frequently used as a measure of retention by public 
health department [32]. We used CD4 count as a proxy measure of patient visit and gap 
in care as a proxy for loss of follow-up. We found these measures to be convenient for 
our analysis, as they are easy to measure. 
  
Our results show that the majority of HIV diagnosed adults in Croatia attended UHID 
regularly. About less than 1 in 10 adults were lost to follow up during the study period.  
Centralization of HIV care to UHID may account for high retention. Because of definition, 
it is common in other institutions to consider patient who moved to other facilities to be 
considered loss of follow up. One important limitation of our definition is that we cannot 
ensure that a patient lost to follow up is not actually included in care in another institu-
tion. 
 
Similarly to access to care, we can suppose that HIV patient who stop coming to UHID 
do so because of cultural rather than financial reasons. As care is free of charge. Cul-
tural reasons related to factor such as homophobia, stigma, environment, and minority, 
work responsibilities may limit retention in care. More studies are needed on our loss of 
follow up population to cluster and later on target this population.  
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6.6. Successful care 
Monitoring of plasma HIV-1 RNA and determination of CD4 cell counts is related to the 
strategy of CART. Current recommendations on the frequency of VL testing after pa-
tients achieve an undetectable VL are mainly based on expert opinion and on the analy-
sis. International Guidelines suggest VL testing every 3-4 month during the first and se-
cond year of CART, then extended to every half a year if viral load suppressed for a year 
and CD4 cell count are >350/ mm³ and adherence to CART is satisfactory [33]. Ade-
quate monitoring of untreated patients is important in terms of appropriate initiation of 
CART and the prevention of AIDS, and also for survival. Determination of VL by PCR is 
available in Croatia since 1997. 
 
Survival of HIV patient 
The 1st year mortality rate of 5% in the study period reveals the consequences of late 
presentation. We believe that since the quality of care was good, if patients were to 
enter care earlier on this would have a direct impact on early mortality. We could 
improve this indicator. Approximately up to 10 people with AIDS die each year. 
The mean CD4 count and proportion of suppressed HIV RNA level are increasing during 
the time period of the analysis, this result is consistent with the increase in the proportion 
of patients receiving CART over the same time period. We do not know if a decline in 
community HIV RNA level has contributed to our low HIV/AIDS level epidemic. 
Some experts consider that a low VL among local HIV population should be enough to 
turn down an HIV epidemic. 
We provided an overview of how Croatia is confronting the HIV continuum of care. This 
continuum of care can be used to inform of the efficacy of public health programs for 
HIV-positive people. And also to facilitate future quality improvement in the management 
of HIV infection in Croatia, by presenting visually where quality of care can be improved 
on a national level. Now that we presented our data, it also be possible to evaluate the 
effects of new policies and guidelines by looking at the outcome of changes on the 
cascade of care.  
Other items were not included such as lipid screening, mental health screening, CART 
resistance test. In reviews, we found that compliance with current guidelines on initiation 
of Pneumocystis jiroveci Pneumonia (PCP) chemoprophylaxis was often used a criteria 
to evaluate HIV care. Very few patients received PCP chemoprophylaxis before 1992, 
today this is routinely done in our care. Therefore we didn’t include this criterion. 
Furthermore, we considered that this criterion would relate more to AIDS patient quality 
of care more than the evaluation of care for our HIV population. These items could be 
included in a future evaluation 
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Standards of care are established to represent a clinically realistic level and at the same 
time exceed mean performance. It is unrealistic to define good care with 100% fulfillment 
of a particular measure. We showed that care of HIV patients improved from 2007 to 
2011, larger proportion of patient are in care and on CART. However up to this day, 
many are not. 
In theory, assessing quality of care could allow comparison of performance between 
institutions. However it is important to note that a wide difference in definition and 
methodology exist between institutions. Therefore looking at definitions is important 
before comparing them. Comparison is often not possible. Up to this date, there were no 
international guidelines regarding the definition and methodology of quality of care 
criteria. In future, standardized definition with similar numerator should allow comparison 
across studies. However this is not essential to evaluate HIV care in Croatia, as we 
considered that our definition should be sufficient to evaluate HIV care over time. 
Our choice of indicators can be debated, but the need for monitoring is indisputable. 
Our assessment ensure that persons living with HIV/AIDS are diagnosed soon after 
acquiring HIV, successfully integrated into medical care, beginning effective antiretroviral 
therapy according to guidelines. 
Also our finding on quality of HIV care in Croatia are encouraging, they do not minimize 
the key role of primary prevention such as condom use, clean needles program, and 
treatment of other STD in general. 
Conclusion: 
With the current paper we aimed to focus on public health attention on the HIV care 
situation in Croatia, by showing encouraging date on quality of care. 
This is the first study that employs a brief panel of indicators based on current 
guidelines, to access the quality of health care in Croatia on the whole HIV diagnosed 
population. 
We investigated HIV care performance using available electronic surveillance date. The 
criteria we used in this evaluation of health care utilization of HIV patients were based on 
current HIV treatment guidelines. We analyzed a wide spectrum of simply measurable 
quality indicators, assimilating several aspects of HIV care from early diagnosis to care 
and survival. In the future, these criteria could be easily monitored up on a yearly basis. 
Our findings suggest that the level of clinical HIV care received by HIV patient in Croatia 
was very good. However, the proportion of late presentation pose an important obstacle 
to reaching an optimal treatment outcome. This means that most patients in care, fully 
benefit of HIV treatment, however we need to be aware that an unknown proportion of 
non-diagnosed HIV infected people does not. 
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